68 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Patel MX, et al. Joint BAP NAPICU evidence-­based consensus guidelines for the clinical management of acute disturbance: de-­escalation and rapid tranquillisation. J Psychopharmacol 2018; 32:601–640.
2. Bak M, et al. The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-­analysis. Eur Psychiatry 2019; 57:78–100.
3. deSouza IS, et al. Rapid tranquilization of the agitated patient in the emergency department: a systematic review and network meta-­analysis. Am J Emerg Med 2022; 51:363–373.
4. Currier GW, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65:386–394.
5. Ganesan S, et al. Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. Int J Psychiatry Clin Pract 2005; 9:199–203.
6. Simpson JR, Jr., et al. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting. J Clin Psychopharmacol 2006; 26:333–335.
7. Hsu WY, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30:230–234.
8. Pratts M, et al. A single-­dose, randomized, double-­blind, placebo-­controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 2014; 130:61–68.
9. Lesem MD, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-­controlled study of inhaled loxapine. Br J Psychiatry 2011; 198:51–58.
10. Kwentus J, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-­controlled clinical trial with inhaled loxapine. Bipolar Disord 2012; 14:31–40.
11. Allen MH, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-­blind, placebo-­controlled trial. J Clin Psychiatry 2011; 72:1313–1321.
12. Karlin DM, et  al. Dexmedetomidine sublingual film: a new treatment to reduce agitation in schizophrenia and bipolar disorders. Ann Pharmacother 2024; 58:54–64.
13. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68:1876–1885.
14. Paris G, et al. Short-­acting intramuscular second-­generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders: a systematic review and network meta-­analysis. Schizophr Res 2021; 229:3–11.
15. Perrin E, et al. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania. Eur Psychiatry 2012; 27:234–239.
16. Ferraz Goncalves JA, et al. Comparison of haloperidol alone and in combination with midazolam for the treatment of acute agitation in an inpatient palliative care service. J Pain Palliat Care Pharmacother 2016; 30:284–288.
17. Chan EW, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-­blind, placebo-­controlled clinical trial. Ann Emerg Med 2013; 61:72–81.
18. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003; 327:708–713.
19. Raveendran NS, et al. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 2007; 335:865.
20. Huf G, et al. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 2007; 335:869.
21. Alexander J, et al. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry 2004; 185:63–69.
22. Dib JE, et al. Rapid tranquillisation in a psychiatric emergency hospital in Lebanon: TREC-­Lebanon: a pragmatic randomised controlled trial of intramuscular haloperidol and promethazine v. intramuscular haloperidol, promethazine and chlorpromazine. Psychol Med 2022; 52:2751–2759.
23. Taylor DM, et al. Midazolam–droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial. Ann Emerg Med 2017; 69:318-­326.e1.
24. Kittipeerachon M, et al. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-­blind randomized trial. Schizophr Res 2016; 176:231–238.
25. Klein LR, et al. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating acute agitation in the emergency department. Ann Emerg Med 2018; 72:374–385.
26. Huang CL, et al. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-­label, randomized controlled trial. J Formos Med Assoc 2015; 114:438–445.
27. Calver L, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med 2015; 66:230-­238.e1.
28. Thiemann P, et al. Prospective study of haloperidol plus lorazepam versus droperidol plus midazolam for the treatment of acute agitation in the emergency department. Am J Emerg Med 2022; 55:76–81.
29. Powney MJ, et al. Haloperidol for psychosis-­induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2012; 11:CD009377.
30. Ostinelli EG, et al. Haloperidol for psychosis-­induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2017; 7:CD009377.

72 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 31. National Institute for Health and Care Excellence. Violence and aggression: short-­term management in mental health, health and community settings. NICE guideline [NG10]. 2015 (reviewed May 2023, last checked December 2024); https://www.nice.org.uk/guidance/NG10. 32. Huf G, et al. Haloperidol plus promethazine for psychosis-­induced aggression. Cochrane Database Syst Rev 2016; 11:CD005146. 33. Kishi T, et  al. Intramuscular olanzapine for agitated patients: a systematic review and meta-­analysis of randomized controlled trials. J Psychiatr Res 2015; 68:198–209. 34. Khokhar MA, et al. Droperidol for psychosis-­induced aggression or agitation. Cochrane Database Syst Rev 2016; 12:CD002830. 35. Satterthwaite TD, et al. A meta-­analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008; 69:1869–1879. 36. van Harten PN, et al. Acute dystonia induced by drug treatment. BMJ 1999; 319:623–626. 37. Pharmacovigilance Working Party. Public Assessment Report on Neuroleptics and Cardiac safety, in particular QT prolongation, cardiac arrhythmias, ventricular tachycardia and torsades de pointes. 2006. 38. Essential Pharma Ltd (Malta). Summary of Product Characteristics. HALDOL Decanoate (haloperidol decanoate) 100 mg/ml solution for injection. 2023 (last checked December 2024); https://www.medicines.org.uk/emc/product/15246/smpc. 39. Miceli JJ, et al. Effects of high-­dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-­ blind, parallel-­group study in patients with schizophrenia or schizoaffective disorder. Clin Ther 2010; 32:472–491. 40. Suzuki A, et al. Histamine H1-­receptor antagonists, promethazine and homochlorcyclizine, increase the steady-­state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 2003; 25:192–196. 41. Lerner Y, et al. Acute high-­dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979; 136:1061–­1064. 42. Martel ML, et al. A large retrospective cohort of patients receiving intravenous olanzapine in the emergency department. Acad Emerg Med 2016; 23:29–35. 43. Cole JB, et al. A prospective observational study of patients receiving intravenous and intramuscular olanzapine in the emergency department. Ann Emerg Med 2017; 69:327–­336.e2. 44. Calver L, et al. A prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit. BMC Psychiatry 2013; 13:225. 45. Mantovani C, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-­blind trial of 4 intramuscular interventions. J Clin Psychopharmacol 2013; 33:306–312. 46. Taylor D, et al. Buccal midazolam for rapid tranquillisation. Int J Psychiatry Clin Pract 2008; 12:309–311. 47. Spain D, et al. Safety and effectiveness of high-­dose midazolam for severe behavioural disturbance in an emergency department with suspected psychostimulant-­affected patients. Emerg Med Australas 2008; 20:112–120. 48. Chan EW, et al. Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: a multi-­centre, double-­blind, randomised clinical trial. EClinicalMedicine 2021; 32:100751. 49. Zaman H, et al. Benzodiazepines for psychosis-­induced aggression or agitation. Cochrane Database Syst Rev 2017; 12:CD003079. 50. Li SF, et al. Safety and efficacy of intravenous combination sedatives in the ED. Am J Emerg Med 2013; 31:1402–1404. 51. MacNeal JJ, et al. Use of haloperidol in PCP-­intoxicated individuals. Clin Toxicol (Phila) 2012; 50:851–853. 52. Mankowitz SL, et al. Ketamine for rapid sedation of agitated patients in the prehospital and emergency department settings: a systematic review and proportional meta-­analysis. J Emerg Med 2018; 55:670–681. 53. Kim HK, et al. Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium. Expert Opin Drug Saf 2021; 20:123–138. 54. Pierre JM. Time to retire haloperidol? For emergency agitation, evidence suggests newer alternatives may be a better choice. Current Psychiatry 2020; 19:18–28. 55. Huf G, et al. Physical restraints versus seclusion room for management of people with acute aggression or agitation due to psychotic illness (TREC-­SAVE): a randomized trial. Psychol Med 2012; 42:2265–2273. 56. Amdisen A, et al. Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleo. Psychopharmacology (Berl) 1986; 90:412–416. 57. Amdisen A, et al. Zuclopenthixol acetate in viscoleo: a new drug formulation. An open Nordic multicentre study of zuclopenthixol acetate in Viscoleo in patients with acute psychoses including mania and exacerbation of chronic psychoses. Acta Psychiatr Scand 1987; 75:99–107. 58. Lowert AC, et al. Acute psychotic disorders treated with 5% zuclopenthixol acetate in ‘Viscoleo’ (‘Cisordinol-­Acutard’), a global assessment of the clinical effect: an open multi-­centre study. Pharmatherapeutica 1989; 5:380–386. 59. Balant LP, et al. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. Pharmacopsychiatry 1989; 22:250–254. 60. Chakravarti SK, et al. Zuclopenthixol acetate (5% in ‘Viscoleo’): single-­dose treatment for acutely disturbed psychotic patients. Curr Med Res Opin 1990; 12:58–65. 61. Baastrup PC, et al. A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatr Scand 1993; 87:48–58. 62. Chin CN, et al. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics. Med J Malaysia 1998; 53:365–371. 63. Taymeeyapradit U, et al. Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients. J Med Assoc Thai 2002; 85:1301–1308. 64. Brook S, et al. A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis. Hum Psychopharmacol 1998; 13:17–20. 65. Chouinard G, et al. A double-­blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1994; 14:377–384.

Schizophrenia and related psychoses CHAPTER 1 66. Al-­Haddad MK, et al. Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses, affective psychoses and paranoid states: a controlled clinical trial. Arab J Psychiatry 1996; 7:44–54. 67. Garriga M, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry 2016; 17:86–128. 68. Wilson MP, et al. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. J Emerg Med 2012; 43:889–896. 69. Villari V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:405–413. 70. Paton C. Benzodiazepines and disinhibition: a review. Psychiatr Bull 2002; 26:460–462. 71. Chan-­Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J 1999; 92:1017–1018. 72. Appleby L, et al. Sudden unexplained death in psychiatric in-­patients. Br J Psychiatry 2000; 176:405–406. 73. Yap YG, et al. Risk of torsades de pointes with non-­cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000; 320:1158–1159. 74. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107:85–95. 75. Penninga EI, et al. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication: a systematic review with meta-­analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016; 118:37–44.